Parkman Healthcare Partners LLC Makes New Investment in Urogen Pharma $URGN

Parkman Healthcare Partners LLC purchased a new stake in Urogen Pharma (NASDAQ:URGN) in the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor purchased 174,064 shares of the company’s stock, valued at approximately $6,406,000.

Several other large investors also recently made changes to their positions in the business. Paradigm Biocapital Advisors LP grew its stake in shares of Urogen Pharma by 6.1% in the 4th quarter. Paradigm Biocapital Advisors LP now owns 4,473,648 shares of the company’s stock worth $104,773,000 after purchasing an additional 257,564 shares during the last quarter. BlackRock Inc. acquired a new stake in Urogen Pharma during the second quarter valued at approximately $117,814,000. Morgan Stanley boosted its holdings in Urogen Pharma by 1.4% during the fourth quarter. Morgan Stanley now owns 2,562,901 shares of the company’s stock worth $60,023,000 after buying an additional 34,455 shares in the last quarter. Soleus Capital Management L.P. bought a new stake in Urogen Pharma during the second quarter worth approximately $29,934,000. Finally, SG Americas Securities LLC grew its position in Urogen Pharma by 20.3% in the first quarter. SG Americas Securities LLC now owns 1,657,846 shares of the company’s stock worth $29,808,000 after buying an additional 280,199 shares during the last quarter. Institutional investors own 91.29% of the company’s stock.

Insider Buying and Selling at Urogen Pharma

In other Urogen Pharma news, insider Mark Schoenberg sold 60,677 shares of the company’s stock in a transaction dated Thursday, August 20th. The stock was sold at an average price of $47.05, for a total value of $2,854,852.85. Following the transaction, the insider directly owned 59,086 shares of the company’s stock, valued at $2,779,996.30. This represents a 50.66% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders have sold 85,899 shares of company stock valued at $3,747,513 over the last 90 days. Corporate insiders own 4.80% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on URGN shares. Oppenheimer upped their price target on Urogen Pharma from $40.00 to $50.00 and gave the company an “outperform” rating in a report on Thursday, July 16th. LADENBURG THALM/SH SH started coverage on Urogen Pharma in a report on Monday, May 11th. They issued a “buy” rating and a $43.00 target price on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Urogen Pharma in a research report on Friday, July 17th. The Goldman Sachs Group restated a “neutral” rating and set a $44.00 price objective on shares of Urogen Pharma in a report on Wednesday, July 15th. Finally, HC Wainwright upped their price objective on shares of Urogen Pharma from $45.00 to $75.00 and gave the company a “buy” rating in a research note on Thursday, August 6th. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Urogen Pharma has a consensus rating of “Moderate Buy” and an average target price of $50.38.

Urogen Pharma Stock Down 1.5%

Shares of NASDAQ:URGN opened at $46.16 on Tuesday. The company’s fifty day moving average is $40.82 and its two-hundred day moving average is $29.32. Urogen Pharma has a 12-month low of $15.86 and a 12-month high of $50.81. The company has a market cap of $2.26 billion, a P/E ratio of -23.31 and a beta of 1.57.

Urogen Pharma (NASDAQ:URGN) last announced its quarterly earnings data on Wednesday, August 5th. The company reported ($0.28) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.26) by ($0.02). The company had revenue of $72.46 million during the quarter, compared to analysts’ expectations of $63.55 million. Equities research analysts anticipate that Urogen Pharma will post -0.2 earnings per share for the current year.

Urogen Pharma Company Profile

UroGen Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for uro-oncology and uro-genital diseases. Founded in 2010 and headquartered in Ra’anana, Israel, with offices in New York, UroGen applies its proprietary RTGel® reverse thermal gel delivery platform to create sustained-release formulations designed for in-office use by urologists.

The company’s lead product, Jelmyto® (mitomycin gel), received U.S. Food and Drug Administration approval in 2020 for the treatment of adults with low-grade upper tract urothelial cancer.